| PEA0062 | Epigenetic silencing siRNA delivered to the nucleus of HIV-1 infected cells via nanoparticle system | E-poster | A20 |
| OAA0203 | Infection outcome in RT-SHIV infected macaques treated early with antiretroviral therapy alone or in combination with the TLR7 agonist vesatolimod | Oral abstract session with live Q&A | A21 |
| OAA0204 | Tyrosine kinase inhibitors promote antiviral resistance in CD4+ T cells against HIV-1 infection even after treatment withdrawal | Oral abstract session with live Q&A | A21 |
| PEA0063 | Dual bromodomain-histone deacetylase inhibitors designed as latency-reversing agents | E-poster | A21 |
| PEA0064 | Chronic HIV-1 patients on treatment with tyrosine kinase inhibitors have a low reservoir size and active cytotoxic cell populations | E-poster | A21 |
| LBPEA01 | Long-acting starch nanoparticle drug delivery system to treat chronic HIV | E-poster | A22 |
| LBPEA03 | Vpu inhibitor BIT225 alters T cell activation and homing plasma membrane receptor expression on CD4+T cells (CD28 and CCR7) and monocyte-derived macrophages (CD80 and CD86) | E-poster | A22 |
| PEA0065 | Alternative 'morning after' rectal or vaginal administration approach for post-exposure prophylaxis of HIV | E-poster | A22 |
| PEA0066 | A pilot study: CRISPR/Cas9 therapy for an effective control of genetically diverse HIV-1 | E-poster | A23 |
| OAALB0103 | CCR5 antibody blockade protects rhesus macaques from rectal SHIV acquisition | Oral abstract session with live Q&A | A24 |